

Resource Summary Report

Generated by [NIF](#) on Jul 29, 2026

Brilliant Violet 650(TM) anti-mouse CD3

RRID:AB_11204249

Type: Antibody

Proper Citation

BioLegend Cat# 100229, RRID:AB_11204249

Antibody Information

URL: http://antibodyregistry.org/AB_11204249

Proper Citation: BioLegend Cat# 100229, RRID:AB_11204249

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 650(TM) anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_11204249

Vendor: BioLegend

Catalog Number: 100229

Record Creation Time: 20250819T230747+0000

Record Last Update: 20250820T042241+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 650(TM) anti-mouse CD3.

No alerts have been found for Brilliant Violet 650(TM) anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 34 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Castelli S, et al. (2026) IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy. *Immunity*, 59(1), 195.

Murphy KC, et al. (2025) MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer. *Cancer research*, 85(22), 4359.

O'Neill E, et al. (2025) Neonatal infection with Bordetella pertussis promotes autism-like phenotypes in mice. *iScience*, 28(1), 111548.

Köhne M, et al. (2025) Satb1 directs the differentiation of TH17 cells through suppression of IL-2 expression. *Cell reports*, 44(7), 115866.

Sun J, et al. (2024) Metabolic regulator LKB1 controls adipose tissue ILC2 PD-1 expression and mitochondrial homeostasis to prevent insulin resistance. *Immunity*, 57(6), 1289.

Chibaya L, et al. (2024) Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. *Science translational medicine*, 16(762), eadj9366.

Ichiyama K, et al. (2024) Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity. *Immunity*, 57(9), 2043.

Prabagar MG, et al. (2024) THE STING AGONIST VB-85247 INDUCES DURABLE ANTITUMOR IMMUNE RESPONSES BY INTRAVESICAL ADMINISTRATION IN A NON-MUSCLE INVASIVE BLADDER CANCER. *Cancer research*.

Seldeslachts L, et al. (2024) Damping excessive viral-induced IFN- γ rescues the impaired anti-Aspergillus host immune response in influenza-associated pulmonary aspergillosis. *EBioMedicine*, 108, 105347.

Miyauchi S, et al. (2024) Protocol to study the immune profile of syngeneic mouse tumor models. *STAR protocols*, 5(3), 103139.

Wang B, et al. (2024) Intermittent clearance of p21-highly-expressing cells extends lifespan and confers sustained benefits to health and physical function. *Cell metabolism*, 36(8), 1795.

Briukhovetska D, et al. (2023) T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis. *Immunity*, 56(1), 143.

Gao G, et al. (2023) *Lactobacillus rhamnosus* ProBio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites. *EBioMedicine*, 91, 104533.

Bhaskar A, et al. (2023) SIRT2 inhibition by AGK2 enhances mycobacteria-specific stem cell memory responses by modulating beta-catenin and glycolysis. *iScience*, 26(5), 106644.

Prokhnjevskaja N, et al. (2023) CD8⁺ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. *Immunity*, 56(1), 107.

Chua BA, et al. (2023) Hematopoietic stem cells preferentially traffic misfolded proteins to aggresomes and depend on autophagy to maintain protein homeostasis. *Cell stem cell*, 30(4), 460.

Jakob MO, et al. (2023) ILC3s restrict the dissemination of intestinal bacteria to safeguard liver regeneration after surgery. *Cell reports*, 42(3), 112269.

Muñoz-Wolf N, et al. (2023) Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles. *Cell reports. Medicine*, 4(1), 100899.

Demaria O, et al. (2022) Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. *Cell reports. Medicine*, 3(10), 100783.

Qu L, et al. (2022) Circular RNA vaccines against SARS-CoV-2 and emerging variants. *Cell*, 185(10), 1728.